JP6865174B2 - Ｅｒｇ癌遺伝子阻害剤としてのアゾフェノール - Google Patents

Ｅｒｇ癌遺伝子阻害剤としてのアゾフェノール Download PDF

Info

Publication number
JP6865174B2
JP6865174B2 JP2017550884A JP2017550884A JP6865174B2 JP 6865174 B2 JP6865174 B2 JP 6865174B2 JP 2017550884 A JP2017550884 A JP 2017550884A JP 2017550884 A JP2017550884 A JP 2017550884A JP 6865174 B2 JP6865174 B2 JP 6865174B2
Authority
JP
Japan
Prior art keywords
erg
compound
alkyl
formula
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017550884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526320A5 (enExample
JP2018526320A (ja
Inventor
エル． ドビ，アルバート
エル． ドビ，アルバート
ダルガード，クリフトン
スリバスタバ，シブ
Original Assignee
ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド
ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド, ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド filed Critical ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド
Publication of JP2018526320A publication Critical patent/JP2018526320A/ja
Publication of JP2018526320A5 publication Critical patent/JP2018526320A5/ja
Application granted granted Critical
Publication of JP6865174B2 publication Critical patent/JP6865174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/04—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017550884A 2015-09-10 2016-09-09 Ｅｒｇ癌遺伝子阻害剤としてのアゾフェノール Active JP6865174B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216839P 2015-09-10 2015-09-10
US62/216,839 2015-09-10
PCT/US2016/051098 WO2017044844A1 (en) 2015-09-10 2016-09-09 Azophenols as erg oncogene inhibitors

Publications (3)

Publication Number Publication Date
JP2018526320A JP2018526320A (ja) 2018-09-13
JP2018526320A5 JP2018526320A5 (enExample) 2019-10-17
JP6865174B2 true JP6865174B2 (ja) 2021-04-28

Family

ID=58240304

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550884A Active JP6865174B2 (ja) 2015-09-10 2016-09-09 Ｅｒｇ癌遺伝子阻害剤としてのアゾフェノール

Country Status (6)

Country Link
US (3) US10238639B2 (enExample)
EP (1) EP3347001B1 (enExample)
JP (1) JP6865174B2 (enExample)
AU (1) AU2016319111B2 (enExample)
CA (1) CA2981188C (enExample)
WO (1) WO2017044844A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6865174B2 (ja) 2015-09-10 2021-04-28 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド Ｅｒｇ癌遺伝子阻害剤としてのアゾフェノール
CA3179323A1 (en) * 2020-06-19 2021-12-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Erg oncogene inhibitors
CN113616645A (zh) * 2021-08-27 2021-11-09 深圳先进技术研究院 一种噻唑基重氮萘酚类化合物在制备治疗恶性脑胶质瘤药物中的应用
WO2023097119A2 (en) * 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0738075B2 (ja) * 1986-12-23 1995-04-26 住友化学工業株式会社 新規なフオトレジスト組成物
US6168843B1 (en) * 1996-12-27 2001-01-02 Tdk Corporation Optical recording medium
WO2010101994A2 (en) * 2009-03-03 2010-09-10 The Regents Of The University Of Michigan Gene fusion targeted therapy
EP3052655B1 (en) 2013-09-30 2018-11-07 Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed
JP6865174B2 (ja) 2015-09-10 2021-04-28 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド Ｅｒｇ癌遺伝子阻害剤としてのアゾフェノール

Also Published As

Publication number Publication date
WO2017044844A1 (en) 2017-03-16
AU2016319111A1 (en) 2017-10-19
AU2016319111B2 (en) 2021-05-06
EP3347001B1 (en) 2023-07-26
CA2981188C (en) 2024-05-28
US10238639B2 (en) 2019-03-26
US20180169074A1 (en) 2018-06-21
US20210299106A1 (en) 2021-09-30
CA2981188A1 (en) 2017-03-16
US11648239B2 (en) 2023-05-16
JP2018526320A (ja) 2018-09-13
EP3347001A1 (en) 2018-07-18
HK1258415A1 (en) 2019-11-08
EP3347001A4 (en) 2019-05-08
US20190336485A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
Bailey et al. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma
US11648239B2 (en) Azophenols as ERG oncogene inhibitors
JP6570042B2 (ja) 官能化ベンゾピラン化合物およびその使用
US12516024B2 (en) KDM4 inhibitors
US20160166553A1 (en) Antimetastatic compounds
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
US20210137898A1 (en) Methods to treat gliomas using a stat3 inhibitor
KR101901001B1 (ko) PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물
TWI522616B (zh) 抗癌藥物之篩選方法及治療癌症之方法
JP6630285B2 (ja) Ｅｒｇ発癌遺伝子陽性癌のための新規阻害剤
EP3893861B1 (en) Treatment and prevention of glioblastoma
JP7345151B1 (ja) 癌治療薬
TWI723030B (zh) 二氫異丹蔘酮ｉ於治療癌症之用途
HK1258415B (en) Azophenols as erg oncogene inhibitors
KR101599259B1 (ko) 혈관 신생작용 관련 질환 치료를 위한 HIF-1α 저해 화합물
EP3664788A1 (en) Compounds for treating von hippel-lindau disease
WO2021137935A2 (en) Novel superebastine against therapy resistant prostate cancer
EA044366B1 (ru) Соединения для лечения болезни фон гиппеля-линдау

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190904

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210405

R150 Certificate of patent or registration of utility model

Ref document number: 6865174

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250